Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
REVENUES
Product revenue, net	$ 0	$ 1,195,675	$ 4,140,090	$ 3,091,745
OPERATING EXPENSES
Cost of products sold	0	129,235	97,637	314,438
Research and development	7,159,686	4,830,327	17,728,516	15,224,896
Selling, general and administrative	2,033,410	3,537,376	8,266,267	10,220,518
Gain on sale of Vyleesi	25,202	0	(7,798,280)	0
Gain on purchase commitment	0	0	0	(1,027,322)
Total operating expenses	9,218,298	8,496,938	18,294,140	24,732,530
Loss from operations	(9,218,298)	(7,301,263)	(14,154,050)	(21,640,785)
OTHER INCOME (EXPENSE)
Investment income	139,273	234,044	272,929	509,006
Foreign currency gain (loss)	215,600	(77,266)	68,653	(352,121)
Interest expense	(1,254)	(3,434)	(13,741)	(18,523)
Offering expenses	0	0	(696,912)	(1,115,765)
Change in fair value of warrant liabilities	429,029	(1,521,413)	(6,962,562)	3,725,895
Total other income (expense), net	782,648	(1,368,069)	(7,331,633)	2,748,492
Loss before income taxes	(8,435,650)	(8,669,332)	(21,485,683)	(18,892,293)
Income tax benefit	0	0	0	(4,674,999)
NET LOSS	$ (8,435,650)	$ (8,669,332)	$ (21,485,683)	$ (14,217,294)
Basic and diluted net loss per common share	$ (0.53)	$ (0.76)	$ (1.53)	$ (1.34)
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share	15,792,421	11,432,380	14,013,848	10,613,830